Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosentan in SSc-ILD (BUILD 2 OL)
NCT00319033Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jul 2004
- Primary completion
- Feb 2006
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
01
Overview
A Phase 3 trial of bosentan in Interstitial lung disease associated with systemic sclerosis (SSc-ILD), sponsored by Actelion Pharmaceuticals Ltd. Started Jul 2004; status: completed.
02
Drugs
bosentan
03
Conditions
Interstitial lung disease associated with systemic sclerosis (SSc-ILD)
Beyond the preview
Go deeper on NCT00319033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00319033.